Episode
Live From WCLC 2026: Tuesday Highlights & Meeting Summary
- Podcast
- Lung Cancer Considered
- Published
- Sep 15, 2026
- Duration seconds
- 2677
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/lung-cancer-considered-246259/episodes/live-from-wclc-2026-tuesday-highlights-meeting-summary/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/lung-cancer-considered-246259/live-from-wclc-2026-tuesday-highlights-meeting-summary.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap key findings from day three of the conference, featuring major advances that move targeted therapies earlier in the treatment of lung cancer. Guests Dr. Julia Rotow, Dr. Roy Herbst, and Dr. Daniel Tan discuss new data from DESTINY-Lung04, ADAURA, and REZILIENT3 and what these findings could mean for clinical practice. Guests: Dr. Julia Rotow Clinical Director and Research Director, Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute Dr. Roy Herbst Director, Dartmouth Cancer Center Professor, Geisel School of Medicine at Dartmouth Dr. Daniel Shao-Weng Tan Senior Consultant Medical Oncologist at Division of Medical Oncology, National Cancer Centre Singapore Professor, Duke-NUS Medical School Senior Clinician-Scientist, Genome Institute of Singapore